Drugs / BW-20805-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07528053 | Apr → Jun 2026 overdue | — | Shanghai Argo Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BW-20805-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07528053 ↗ |
| Route | Subcutaneous | “Group 3 will receive SC administrations of BW-20805-2 on Day1.” NCT07528053 ↗ |